Fluidigm Corporation (FLDM) News
Filter FLDM News Items
FLDM News Results
|Loading, please wait...|
FLDM News Highlights
- For FLDM, its 30 day story count is now at 5.
- Over the past 11 days, the trend for FLDM's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
Latest FLDM News From Around the Web
Below are the latest news stories about Fluidigm Corp that investors may wish to consider to help them evaluate FLDM as an investment opportunity.
Lab-on-a-chip and Microarrays (Biochip) Market 2021 Segments Analysis and Key Company Profiles | Abbott Laboratories, Agilent Technologies, Bio-Rad Laboratories Inc., GE Healthcare, Roche Holding AG, Fluidigm Corporation, Thermo Fisher Scientific, etc.
Biochips are increasingly being used in the field of biomedical and biotechnological research. With the advancement of technology, there has been a rise in the adoption of biochips in proteomics, such as in microarrays. The advantages of protein biochips include
Tumor Genomics Market Thundering USD 56 Bn by 2021-28 with Bio-Rad Laboratories, Abbott, Agilent, Danaher, F. Hoffmann-La Roche, Fluidigm, General Electric Company, Illumina, Merck, Myriad Genetics, PerkinElmer, QIAGEN, Siemens, Thermo Fisher Scientific
The Tumor Genomics Market is expected to reach a market size of USD 56.54 Billion, to register a CAGR of +12% by 2028. Tumor genomic assays (or tests) analyze a sample of a cancer tumor to see how active certain
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that Chris Linthwaite, President and CEO, and Vikram Jog, Chief Financial Officer, will participate in investor meetings and present updates regarding Fluidigms business strategy and financial performance at the following investor event:
CyTOF and Maxpar Direct Technologies Utilized in Study Characterizing Immune and Inflammatory Responses in Pregnant Women Infected with SARS-CoV-2
Findings in Nature Communications Provide Insights That May Help Guide Patient Care Research Study Conducted in Collaboration with Fluidigm’s Therapeutic Insights Services SOUTH SAN FRANCISCO, Calif., Aug. 31, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced the publication of new data further validating the potential of its mass cytometry technologies, inclu
While not a mind-blowing move, it is good to see that the Fluidigm Corporation ( NASDAQ:FLDM ) share price has gained...
SOUTH SAN FRANCISCO, Calif., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that company management will participate in the following investor event:
Ultivue Announces Co-Marketing Agreement with Fluidigm for Biomarker Imaging Solutions for Precision Medicine
CAMBRIDGE, Mass. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Ultivue, Inc. and Fluidigm Corporation (Nasdaq:FLDM) today announced a co-marketing agreement in which the companies will offer customers a comprehensive portfolio of workflow solutions for biomarker discovery and drug development. Ultivue, a leader in advancing precision medicine solutions by accelerating tissue biomarker discovery and validation develops unique assays for use in multiplex immunofluorescence imaging and analysis.
Biochips Market 2021: Competitive Landscape, Statistics and Top Manufacturers Forecast 2028 | Abbott Laboratories (US), Agilent Technologies Inc. (US), PerkinElmer Inc. (US), Fluidigm Corporation (US)
Stratagem Market Insights has recently published a research report titled, Global Biochips Market Insights, Size, Share, Growth, Opportunities, Emerging Trends, Forecast to 2028. The report is a compilation of comprehensive research studies on various aspects of the global Biochips market.
Fluidigm Announces Co-Marketing Agreement with Ultivue for Biomarker Imaging Solutions for Precision Medicine
Objective of Agreement is Comprehensive Portfolio for Biomarker Discovery and Drug Development Objective of Agreement is Comprehensive Portfolio for Biomarker Discovery and Drug Development
Fluidigm Announces Collaboration Agreement with Imaging CRO ImaBiotech to Increase Biopharma Access to Imaging Mass Cytometry
Collaboration Focusing on Advancing CRO Capabilities in Drug Development Utilizing the Hyperion Imaging System Collaboration Focusing on Advancing CRO Capabilities in Drug Development Utilizing the Hyperion Imaging System